Compare Deere & Company (DE) vs Summit Therapeutics Inc (SMMT) Price & Performance

Deere & Company (DE) trades at $619.82, up 1.73% in the last session, reflecting positive momentum amid a bullish technical signal. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $6.55 surpassing the $5.70 forecast. However, revenue declined to $44.67 billion in 2025, and net income margin compressed to 10.33%. The stock's valuation multiples, including a P/E of 35.01, are elevated relative to historical norms, while analyst consensus leans moderate buy with a $669.79 price target.

The outlook for DE hinges on agricultural demand recovery, but near-term risks include weak North American equipment sales and margin pressure. Upside potential exists if earnings sustain beats and cost controls improve profitability, yet investors face cyclical industry exposure and high debt levels. The current price near resistance at $620 suggests cautious entry points may be prudent pending Q2 2026 results.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.